Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. Holkova B, et al. Among authors: zingone a. Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7. Clin Cancer Res. 2016. PMID: 26446942 Free PMC article. Clinical Trial.
Control of autophagic cell death by caspase-10 in multiple myeloma.
Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E, Nair V, Kruhlak MJ, Zingone A, Landgren O, Staudt LM. Lamy L, et al. Among authors: zingone a. Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 Mar 28. Cancer Cell. 2013. PMID: 23541952 Free PMC article.
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.
Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O. Zingone A, et al. Cytokine. 2014 Oct;69(2):294-7. doi: 10.1016/j.cyto.2014.05.017. Epub 2014 Jul 17. Cytokine. 2014. PMID: 25043675 Free PMC article.
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Korde N, et al. Among authors: zingone a. JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010. JAMA Oncol. 2015. PMID: 26181891 Free PMC article. Clinical Trial.
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. Cherry BM, et al. Among authors: zingone a. Leuk Lymphoma. 2013 Oct;54(10):2215-8. doi: 10.3109/10428194.2013.764419. Epub 2013 Jul 29. Leuk Lymphoma. 2013. PMID: 23311294 Free PMC article.
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O. Korde N, et al. Among authors: zingone a. Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. Haematologica. 2014. PMID: 24658821 Free PMC article. Clinical Trial. No abstract available.
104 results